Opinion

Opinion: Sarepta’s Collapse Is a Case Study in the High Cost of Withholding Trust

Author: Yehuda Leibler Over the past few days, Sarepta Therapeutics reminded us that in public markets, credibility is not just a nice-to-have. It is a core asset. Once lost, it is incredibly challenging to recover. In less than 48 hours, Sarepta saw its share price rise nearly 20